Overview

A Study to Evaluate a Potassium Normalization Treatment Regimen Including Sodium Zirconium Cyclosilicate (ZS) Among Patients With S-K ≥5.8

Status:
Completed

Trial end date:
2018-12-21

Target enrollment:

Participant gender:

Summary

The study is designed to determine if ZS 10g administered up to three times over 10h added to insulin and glucose in patients presenting with hyperkalemia will prove tolerable and efficacious. Patients will receive ZS or Placebo on top of standard of care treatment with insulin and glucose.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Insulin
Insulin, Globin Zinc